Comprehensive Analysis of Pharmaceutical Development Trends, 2007 [Vol. 1: Major Japan-based Pharmaceutical Companies]

Outline of the report

Mitsubishi Tanabe’s post-merger activities are well underway
The proportion of international sales shows even higher growth due to rapidly-growing international pharmaceutical business, e.g., Eisai from 54% to 61%, Takeda from 44% to 49%, and Astellas from 42% to 49%.
R&D restructuring efforts are being intensified; Eisai / Takeda
Sale or spin-off of non-pharmaceutical business is currently in progress; Takeda / Daiichi Sankyo / Shionogi / Kyowa Hakko
Consolidations/spin-offs of production units, and production outsourcing are becoming popular; Astellas / Daiichi Sankyo / Tanabe / Mitsubishi Welpharma / Mochida / Dainippon Sumitomo
Globalization of research and development activities are in progress.
Advance is seen in a comprehensive review of the area of investigation as well as developmental drugs, with the R&D focus becoming more targeted, and more affiliations/alliances being underway.
’Comprehensive Analysis of Pharmaceutical Development Trends, 2007’ is a new report published by Seed Planning, Inc. comprising average 24 pages of detailed profiles per company.
Separately probed organizational structure, R&D structure, and R&D headcount is also available.

Title of the report	Comprehensive Analysis of Pharmaceutical Development Trends, 2007 [Vol. 1: Major Japan-based Pharmaceutical Companies]
Date of issue	10/10/07
Volume	A4 / 474 pages
Price	95,000JPY
Produced by	Seed Planning, Inc.
Note	This report is written in Japanese. Customers who need an English version:Please contact us.
Category	Pharmaceutical products / compaines

I. Analysis of the survey results

II. Case study

III. Trends of investigational drugs

SPI-information is a website for selling marketing research reports produced in Japan and worldwide.